Generated by AI
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.
Website7495 New Horizon Way
Frederick, MD, 21703
United States
The latest articles about RNAC.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomy
Summary of Jun 9's posts. Generated by AI.
Summary of Mar 22's posts. Generated by AI.
Summary of Jul 2's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Investors talking about RNAC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.